Bayer AG Buys Dihon Pharmaceutical Group For About $680 Million To Add Traditional Chinese Medicine To Product Line

Published: Feb 27, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bayer said it would buy privately held Dihon Pharmaceutical Group Co, a maker of traditional herbal Chinese medicines (TCM), as the German drugmaker pushes to become the world's largest non-prescription medicines group. With China's healthcare spending forecast to nearly triple to $1 trillion by 2020 from $357 billion in 2011, according to consulting firm McKinsey, the country is a magnet for makers of medicines and medical equipment, but many patients remain strongly attached to traditional approaches. "What's growing the most within Chinese healthcare is traditional medicine. It's a strong part of their culture," said Lilian Montero, a healthcare analyst at Swiss bank Julius Baer.

Help employers find you! Check out all the jobs and post your resume.

Back to news